On April 16, 2009, Pharmacyclics, Inc. a Delaware corporation (the "Registrant"), entered into a global strategic alliance with Servier, the leading French independent pharmaceutical company. The alliance will focus on the research, development, and commercialization of Pharmacyclics' PCI-24781, an orally active, novel, small molecule inhibitor of Pan HDAC enzymes, that is currently in Phase I/II clinical trials in the United States and being developed for the treatment of solid tumors and hematologic malignancies. Under the terms of the agreement, the Registrant grants to Servier the exlusive right to develop and commercialize the Pan HDAC inhibitor product worldwide except for the United States. Servier will pay a royalty to the Registrant on sales outside of the United States. The Registrant will continue to own all rights within the United States. The Registrant will also receive from Servier upfront payments totaling $11.0 million on signing the contract and an additional guaranteed $4.0 million for research collaboration over a 24 month period, paid in equal increments every 6 months with the initial payment due October 1, 2009. Servier will pay for all development costs outside the United States. In addition, the Registrant will receive up to $24.5 million based on the achievement of certain milestones up to and including commercialization.

The foregoing description is qualified in its entirety by reference to the Registrant's Press Release dated April 17, 2009, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.

On April 17, 2009, the Registrant issued a press related to the matters set forth in Item 1.01. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

(d) Exhibits.

                    Exhibit No.    Description
                       99.1        Press Release of Pharmacyclics, Inc. dated April 17, 2009.


--------------------------------------------------------------------------------
--------------------------------------------------------------------------------